The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection

Kidney International

Volumn 84, Issue 3, 2013, Pages 468-481

  Hu, Ming Chang ^a   Shi, Mingjun ^a   Cho, Han J ^a   Zhang, Jianning ^a   Pavlenco, Alevtina ^b   Liu, Shuzhen ^c   Sidhu, Sachdev ^b   Huang, Lily J S ^c   Moe, Orson W ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

cytotoxicity; erythropoietin; erythropoietin receptor; Klotho; NRK cell; oxidative stress

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYDROGEN PEROXIDE; JANUS KINASE 2; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; STAT5 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; KIDNEY INJURY; KIDNEY TUBULE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; RENAL PROTECTION; REPERFUSION INJURY; TRANSGENE;

ACUTE KIDNEY INJURY; ANIMALS; CELL LINE; CYTOPROTECTION; DISEASE MODELS, ANIMAL; GLUCURONIDASE; HUMANS; HYDROGEN PEROXIDE; JANUS KINASE 2; KIDNEY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ERYTHROPOIETIN; RNA, SMALL INTERFERING; STAT5 TRANSCRIPTION FACTOR;

EID: 84883456412     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.149     Document Type: Article

References (97)

1. David RB, Lim GB, Moritz KM et al. Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus. Mol Cell Endocrinol 2002; 188: 207-218.
2. Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 1997; 273: R1829-R1844.
3. Wintour EM, Butkus A, Earnest L et al. The erythropoietin gene is expressed strongly in the mammalian mesonephric kidney. Blood 1996; 88: 3349-3353.
4. Wu H, Liu X, Jaenisch R et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67.
5. Bartesaghi S, Marinovich M, Corsini E et al. Erythropoietin: A novel neuroprotective cytokine. Neurotoxicology 2005; 26: 923-928.
6. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the bloodbrain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-10531.
7. Tang YD, Hasan F, Giordano FJ et al. Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: Results of a double-blind, placebo-controlled, randomized trial. Am Heart J 2009; 158: 941-947.
8. Smith KJ, Bleyer AJ, Little WC et al. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59: 538-548.
9. Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-4806.
10. Li L, Takemura G, Li Y et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006; 113: 535-543.
11. Johnson DW, Pat B, Vesey DA et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806-1813.
12. Bi B, Guo J, Marlier A et al. Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol 2008; 295: F1017-F1022.
13. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009; 18: 15-20.
14. Brines M, Cerami A. Erythropoietin-mediated tissue protection: Reducing collateral damage from the primary injury response. J Intern Med 2008; 264: 405-432.
15. Sharples EJ, Thiemermann C, Yaqoob MM. Mechanisms of disease: Cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol 2005; 1: 87-97.
16. Imamura R, Moriyama T, Isaka Y et al. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 2007; 83: 1371-1379.
17. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: A tale of two receptors. Blood Purif 2010; 29: 86-92.
18. Von Salisch S, Klar M, Thurisch B et al. Gata4 and Sp1 regulate expression of the erythropoietin receptor in cardiomyocytes. J Cell Mol Med 2010; 15: 1963-1972.
19. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31.
20. Liu C, Shen K, Liu Z et al. Regulated human erythropoietin receptor expression in mouse brain. J Biol Chem 1997; 272: 32395-32400.
21. Zhang Q, Zhang J, Moe OW et al. Synergistic upregulation of erythropoietin receptor (EPO-R) expression by sense and antisense EPO-R transcripts in the canine lung. Proc Natl Acad Sci USA 2008; 105: 7612-7617.
22. Echigoya MH, Obikane K, Nakashima T et al. Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron Exp Nephrol 2005; 100: E21-e29.
23. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820.
24. Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-3978.
25. Ammarguellat F, Gogusev J, Drueke TB. Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 1996; 11: 687-692.
26. Rundqvist H, Rullman E, Sundberg CJ et al. Activation of the erythropoietin receptor in human skeletal muscle. Eur J Endocrinol 2009; 161: 427-434.
27. Jelkmann W, Bohlius J, Hallek M et al. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.
28. Nakano M, Satoh K, Fukumoto Y et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007; 100: 662-669.
29. Tsai PT, Ohab JJ, Kertesz N et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006; 26: 1269-1274.
30. Sinclair AM, Coxon A, McCaffery I et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010; 115: 4264-4272.
31. Elliott S, Busse L, McCaffery I et al. Identification of a sensitive antierythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods 2010; 352: 126-139.
32. Swift S, Ellison AR, Kassner P et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010; 115: 4254-4263.
33. Sinclair AM, Rogers N, Busse L et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 2008; 98: 1059-1067.
34. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
35. Chen CD, Podvin S, Gillespie E et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104: 19796-19801.
36. Bloch L, Sineshchekova O, Reichenbach D et al. Klotho is a substrate for alpha-, beta- and gamma-secretase. FEBS Lett 2009; 583: 3221-3224.
37. Hu M-C, Shiizaki K, Kuro-o M et al. Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Ann Rev Physiol 2013; 75: 503-533.
38. Hu MC, Shi M, Zhang J et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010; 78: 1240-1251.
39. Sugiura H, Yoshida T, Mitobe M et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant 2010; 25: 60-68.
40. De Beuf A, Verhulst A, Helbert MF et al. Tubular erhtyropoietin receptor expression mediates erythropoietin-induced renoprotection. Hematol J 2009; 3: 1-10.
41. Sawyer ST, Hankins WD. The functional form of the erythropoietin receptor is a 78-kDa protein: Correlation with cell surface expression, endocytosis, and phosphorylation. Proc Natl Acad Sci USA 1993; 90: 6849-6853.
42. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136.
43. Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829-1833.
44. Lash LH, Putt DA, Matherly LH. Protection of NRK-52E cells, a rat renal proximal tubular cell line, from chemical-induced apoptosis by overexpression of a mitochondrial glutathione transporter. J Pharmacol Exp Ther 2002; 303: 476-486.
45. Zhang J, Bobulescu IA, Goyal S et al. Characterization of Na+/H+ exchanger NHE8 in cultured renal epithelial cells. Am J Physiol Renal Physiol 2007; 293: F761-F766.
46. Zhao L, Dong H, Zhang CC et al. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J Biol Chem 2009; 284: 26988-26998.
47. Belenkov AI, Shenouda G, Rizhevskaya E et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004; 3: 1525-1532.
48. Seong SR, Lee JW, Lee YK et al. Stimulation of cell growth by erythropoietin in RAW264.7 cells: Association with AP-1 activation. Arch Pharm Res 2006; 29: 218-223.
49. Wenker SD, Chamorro ME, Vota DM et al. Differential antiapoptotic effect of erythropoietin on undifferentiated and retinoic acid-differentiated SHSY5Y cells. J Cell Biochem 2010; 110: 151-161.
50. De Beuf A, Hou XH, D'Haese PC et al. Epoetin delta reduces oxidative stress in primary human renal tubular cells. J Biomed Biotechnol 2010; 2010: 395785.
51. Goldwasser E. Erythropoietin and the differentiation of red blood cells. Fed Proc 1975; 34: 2285-2292.
52. Longmore GD, Watowich SS, Hilton DJ et al. The erythropoietin receptor: Its role in hematopoiesis and myeloproliferative diseases. J Cell Biol 1993; 123: 1305-1308.
53. Breggia AC, Wojchowski DM, Himmelfarb J. JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells. Am J Physiol Renal Physiol 2008; 295: F1689-F1695.
54. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001; 412: 641-647.
55. Huang LJ, Shen YM, Bulut GB. Advances in understanding the pathogenesis of primary familial and congenital polycythaemia. Br J Haematol 2010; 148: 844-852.
56. Kondyli M, Gatzounis G, Kyritsis A et al. Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors. J Neurooncol 2010; 100: 157-164.
57. Marti HH, Wenger RH, Rivas LA et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666-676.
58. Kim HW, Kim JL, Lee HK et al. Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Curr Eye Res 2009; 34: 976-987.
59. Wright GL, Hanlon P, Amin K et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004; 18: 1031-1033.
60. Giatromanolaki A, Fiska A, Pitsiava D et al. Erythropoietin receptors in endometrial carcinoma as related to HIF1{alpha} and VEGF expression. In Vivo 2009; 23: 699-703.
61. Selzer E, Wacheck V, Kodym R et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000; 10: 421-426.
62. Sfacteria A, Mazzullo G, Bertani C et al. Erythropoietin receptor expression in canine mammary tumor: An immunohistochemical study. Vet Pathol 2005; 42: 837-840.
63. Leo C, Horn LC, Rauscher C et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 2006; 12: 6894-6900.
64. Arcasoy MO, Amin K, Vollmer RT et al. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2005; 18: 421-430.
65. Eccles TG, Patel A, Verma A et al. Erythropoietin and the erythropoietin receptor are expressed by papillary thyroid carcinoma from children and adolescents. Expression of erythropoietin receptor might be a favorable prognostic indicator. Ann Clin Lab Sci 2003; 33: 411-422.
66. Kase S, Yoshida K, Osaki M et al. Expression of erythropoietin receptor in human Merkel cell carcinoma of the eyelid. Anticancer Res 2006; 26: 4535-4537.
67. Lee YS, Vortmeyer AO, Lubensky IA et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 2005; 11: 1059-1064.
68. Ikegaya N, Yamamoto T, Takeshita A et al. Elevated erythropoietin receptor and transforming growth factor-beta1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol 2000; 11: 928-935.
69. Foster DJ, Moe OW, Hsia CC. Upregulation of erythropoietin receptor during postnatal and postpneumonectomy lung growth. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1107-L1115.
70. Beleslin-Cokic BB, Cokic VP, Wang L et al. Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells. Cytokine 2011; 54: 129-135.
71. Teng R, Gavrilova O, Suzuki N et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun 2011; 2: 520.
72. Gong Q, Jiang H, Wei X et al. Expression of erythropoietin and erythropoietin receptor in human dental pulp. J Endod 2010; 36: 1972-1977.
73. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907-14912.
74. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int 2006; 70: 246-250.
75. Laugsch M, Metzen E, Svensson T et al. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008; 122: 1005-1011.
76. Elliott S, Busse L, Bass MB et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107: 1892-1895.
77. Paragh G, Kumar SM, Rakosy Z et al. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol 2009; 174: 1504-1514.
78. Cassis P, Gallon L, Benigni A et al. Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney Int 2012; 81: 903-918.
79. Doleschel D, Mundigl O, Wessner A et al. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts. J Nucl Med 2012; 53: 304-311.
80. Jie KE, Verhaar MC, Cramer MJ et al. Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006; 291: F932-F944.
81. Fishbane S, Ragolia L, Palaia T et al. Cytoprotection by darbepoetin/ epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int 2004; 65: 452-458.
82. Pallet N, Bouvier N, Legendre C et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010; 61: 71-75.
83. Marrero MB, Venema RC, Ma H et al. Erythropoietin receptor-operated Ca2+ channels: Activation by phospholipase C-gamma 1. Kidney Int 1998; 53: 1259-1268.
84. Li J, Vesey DA, Johnson DW et al. Erythropoietin reduces cisplatininduced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 2007; 6: 1944-1950.
85. Rodrigues CE, Sanches TR, Volpini RA et al. Effects of continuous erythropoietin receptor activator in sepsis-induced acute kidney injury and multi-organ dysfunction. PLoS One 2012; 7: E29893.
86. Yamamoto M, Clark JD, Pastor JV et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005; 280: 38029-38034.
87. Liu H, Fergusson MM, Castilho RM et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317: 803-806.
88. Shimada T, Takeshita Y, Murohara T et al. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 2004; 110: 1148-1155.
89. Kusaba T, Okigaki M, Matui A et al. Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci USA 2010; 107: 19308-19313.
90. Saito Y, Nakamura T, Ohyama Y et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 2000; 276: 767-772.
91. Doi S, Zou Y, Togao O et al. Klotho inhibits transforming growth factorbeta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011; 286: 8655-8665.
92. Hu MC, Shi M, Zhang J et al. Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24: 3438-2450.
93. Fuster DG, Zhang J, Shi M et al. Characterization of the sodium/hydrogen exchanger NHA2. J Am Soc Nephrol 2008; 19: 1547-1556.
94. Fellouse FA, Sidhu SS. Making antibodies in bacteria. In: Making and using antibodies. Howard GC and Kaser MR (eds). CRC Press: Boca Raton, FL, 2007; pp 157-180.
95. Fellouse FA, Esaki K, Birtalan S et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol 2007; 373: 924-940.
96. Bulut GB, Sulahian R, Ma Y et al. Ubiquitination regulates the internalization, endolysosomal sorting, and signaling of the erythropoietin receptor. J Biol Chem 2011; 286: 6449-6457.
97. Sulahian R, Cleaver O, Huang LJ. Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. Blood 2009; 113: 5287-5297.